Written by The Fusion Biopsy Market is gaining importance as healthcare systems seek more precise diagnostic methods for cancer and other complex diseases. Market Research Future estimates that the market will grow from USD 0.915 billion in 2025 to USD 1.913 billion by 2035, representing a CAGR of 7.65%. Rising healthcare expenditure, increasing cancer prevalence, and growing adoption of minimally invasive techniques are among the factors supporting this expansion.
Fusion biopsy technologies benefit from the integration of advanced imaging methods with diagnostic procedures. MRI and ultrasound guidance can improve lesion targeting, while newer imaging platforms are being developed to provide better visualization and procedural support. Increasing research and development investment is also encouraging the introduction of technologies designed to improve biopsy efficiency and diagnostic accuracy.
The market is segmented across DNA, RNA, and protein tech targets, with DNA holding the largest share. Multi-gene panels lead the product segment because they can evaluate multiple genetic alterations simultaneously, while companion diagnostics are growing alongside targeted and personalized therapies. Oncology remains the largest application, and NGS leads the technology segment.
Regional growth is led by North America, which holds about 45% of the market, while Europe accounts for around 30%. Asia-Pacific represents approximately 20% and is witnessing increasing investment in healthcare infrastructure and diagnostic technologies. Expansion of cancer screening, improved access to advanced imaging, and development of precision medicine are expected to create further opportunities for fusion biopsy technologies.
Strengthen your strategy with data-backed research insights:
Smart Medical Devices Market Size
Smart Medical Devices Market Share
Smart Medical Devices Market Trends